Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press113710.17650/1994-4098-2023-19-3-43-53MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИModern possibilities for the correction of menopausal symptoms in patients with breast cancer, depending on the molecular biological characteristics of the tumor (literature review)Современные возможности коррекции менопаузальных симптомов у больных раком молочной железы с учетом молекулярно-биологических характеристик опухоли (обзор литературы)https://orcid.org/0000-0001-8814-636XVysotskayaI. V.ВысоцкаяИ. В.
Russian Federation

Irina Viktorovna Vysotskaya

Build. 2, 8 Trubetskaya St., Moscow 119991

Ирина Викторовна Высоцкая

119991 Москва, ул. Трубецкая, 8, стр. 2

vysotskaya.irinavic63@gmail.comhttps://orcid.org/0000-0003-4893-8770KimE. A.КимЕ. А.
Russian Federation

Build. 2, 8 Trubetskaya St., Moscow 119991

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0001-9432-1064GeletkoM. V.ГелеткоМ. В.
Russian Federation

Build. 2, 8 Trubetskaya St., Moscow 119991

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0009-0005-6328-9109MisrikhanovaF. E.МисрихановаФ. Э.
Russian Federation

Build. 2, 8 Trubetskaya St., Moscow 119991

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0003-0040-3136KirsanovV. Yu.КирсановВ. Ю.
Russian Federation

Build. 2, 8 Trubetskaya St., Moscow 119991

119991 Москва, ул. Трубецкая, 8, стр. 2

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) Минздрава России2710202319343532710202327102023https://ojrs.abvpress.ru/ojrs/article/view/1137

Breast cancer (BC) ranks first in cancer incidence among women. For successful treatment of BC, depending on the molecular type and stage of the disease, chemotherapy is used, the side effects of which are manifested by menopausal symptoms, sexual dysfunction, and depressive states. However, not all patients after BC receive appropriate therapy for menopausal symptoms, what significantly worsens their quality of life. One of the symptoms that brings the most severe discomfort is the vasomotor symptom, a form of temperature dysfunction with peripheral vasodilation and increased cutaneous blood flow that results in increased heat loss. There are several types of drugs that are used to prevent menopausal symptoms in patients taking endocrine chemotherapy, many of which are in the experimental phase of development. In this review, we will try to identify proven effective and safe methods for correcting menopausal symptoms in women who underwent chemotherapy and endocrine therapy for BC.

Рак молочной железы (РМЖ) занимает 1-е место в структуре онкологической заболеваемости среди женщин. Для успешного лечения РМЖ в зависимости от молекулярного типа опухоли и стадии заболевания используют химиотерапию, побочные эффекты которой проявляются менопаузальными симптомами, сексуальной дисфункцией, депрессивными состояниями. Однако не все пациентки получают правильно подобранную терапию менопаузальных симптомов, ассоциированных с терапией РМЖ, что значительно ухудшает их качество жизни. Одним из симптомов, приносящих наиболее сильный дискомфорт, является вазомоторный симптом – форма температурной дисфункции, связанной с периферической вазодилатацией, усилением кожного кровотока и повышением температуры тела, что приводит к чрезмерной потере тепла. Для предотвращения менопаузальных симптомов у пациенток, получающих адъювантную гормонотерапию, рассматриваются различные препараты, многие из которых находятся на экспериментальном этапе разработки. В данном обзоре мы рассмотрели доказанно эффективные и безопасные методы коррекции менопаузальных симптомов у женщин, перенесших химиои гормонотерапию при РМЖ.

menopausal symptomsbreast cancervasomotor symptomsadjuvant hormonal therapycorrection of menopausal symptomschemotherapyendocrine therapyserotonin reuptake inhibitorsgabapentinfesolinetantKlimadynontriple negative breast cancerBRCA mutationsHER2-positive breast cancercimicifugaменопаузальные симптомырак молочной железывазомоторные симптомыадъювантная гормонотерапиякоррекция менопаузальных симптомовхимиотерапияэндокринная терапияингибиторы обратного захвата серотонинагабапентинфезолинетантКлимадинонтрижды негативный рак молочной железыBRCA-мутацииHER2-положительный рак молочной железыцимицифугаThe work was performed without external fundingРабота выполнена без спонсорской поддержкиMazor M., Lee K., Dhruva A. et al. Menopausal-related symptoms in women one year after breast cancer surgery. J Pain Symptom Manage 2018;55(4):1138–51.e1. DOI: 10.1016/j.jpainsymman.2017.11.030Peate M., Saunders C., Cohen P. et al. Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors. Breast Cancer Res Treat 2021;187:427–35. DOI: 10.1007/s10549-021-06117-7Rozenberg S., Di Pietrantonio V., Vandromme J. Hormone therapy during menopause and the risk of breast cancer. Best Pract Clin Endocrinol 2021;35(6):101577. DOI: 10.1016/j.beem.2021.101577Wang S.M., Pfeiffer R.M., Gierach G.L. et al. Use of postmenopausal hormone therapies and risk of histologyand hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. Breast Cancer Res 2020;22(129). DOI: 10.1186/s13058-020-01365-9Marchetti C., De Felice F., Boccia S. et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit Rev Oncol Hematol 2018;132:111–5. DOI: 10.1016/j.critrevonc.2018.09.018Rozenberg S., Di Pietrantonio V., Vandromme J., Gilles C. Menopausal hormone therapy and breast cancer risk. Best Pract Res Clin Endocrinol Metab 2021;35(6):101577. DOI: 10.1016/j.beem.2021.101577Poorolajal J., Heidarimoghis F., Karami M. et al. Factors for the primary prevention of breast cancer: A meta-analysis of prospective cohort studies. J Res Health Sci 2021;21(3):e00520. DOI: 10.34172/jrhs.2021.57Garcia-Recio S., Gascón P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int 2015;2015:495704. DOI: 10.1155/2015/495704Page N.M. New challenges in the study of the mammalian tachykinins. Peptides 2005;26(8):1356–68. DOI: 10.1016/j.peptides.2005.03.030Rance N.E., Dacks P.A., Mittelman-Smith M.A. et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol 2013;34(3):211–27. DOI: 10.1016/j.yfrne.2013.07.003Rometo A.M., Krajewski S.J., Voytko M.L., Rance N.E. Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys. J Clin Endocrinol Metab 2007;92(7):2744–50. DOI: 10.1210/jc.2007-0553Rance N.E., Young W.S. Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology 1991;128(5):2239–47. DOI: 10.1210/endo-128-5-2239Trower M., Anderson R.A., Ballantyne E. et al. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause 2020;27(5):498–505. DOI: 10.1097/GME.0000000000001500Simon J., Anderson R.A., Ballantyne E. et al. OR11-03 NT-814, a non-hormonal dual neurokinin 1,3 receptor antagonist markedly improves vasomotor symptoms in post-menopausal women; results of a randomised, double-blind, placebo-controlled, dose-finding study (SWITCH-1). J Endocr Soc 2020;4(Suppl 1):OR11-03. DOI: 10.1210/jendso/bvaa046.2071Bansal R., Aggarwal N. Menopausal hot flashes: A concise review. J Midlife Health 2019;10(1):6–13. DOI: 10.4103/jmh.JMH_7_19Walling A.D. Gabapentin reduces hot flashes in breast cancer survivors. Am Fam Physician 2006;73(6):1100–2.Raus K., Brucker C., Gorkow C., Wuttke W. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause 2006;13(4):678–91. DOI: 10.1097/01.gme.0000196813.34247.e2Gordeeva G.D. Efficacy of phyto-pharmaceutical climadinon in women with menopausal syndrome of various genesis. Reproduktivnoe zdorovye zhenshchiny = Women’s Reproductive Health 2003;1(13):84–90. (In Russ.)Гордеева Г.Д. Эффективность применения фитопрепарата Климадинон у женщин с менопаузальным синдромом различного генеза. Репродуктивное здоровье женщины 2003;1(13):84–90.Wuttke W., Raus K., Gorkow C. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placeboand conjugated estrogens-controlled study. Maturitas 2006;55S:S83–S91. DOI: 10.1016/j.maturitas.2006.06.020Trant A.A., Chagpar A., Wei W. et al. The effect of Black cohosh on Ki67 expression and tumor volume: A pilot study of ductal carcinoma in situ patients. Integr Cancer Ther 2022;21:15347354221137290. DOI: 10.1177/15347354221137290Drewe J., Boonen G., Culmsee C. Treat more than heat – New therapeutic implications of Cimicifuga racemosa through AMPK-dependent metabolic effects. Phytomedicine 2022;100:154060. DOI: 10.1016/j.phymed.2022.154060Mann E., Smith M., Hellier J., Hunter M.S. A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): Trial protocol. BMC Cancer 2011;11:44. DOI: 10.1186/1471-2407-11-44Ayers B., Smith M., Hellier J. et al. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): A randomized controlled trial. Menopause 2012;19(7):749–59. DOI: 10.1097/gme.0b013e31823fe835Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22(11):1155–72; quiz 1173–4. DOI: 10.1097/GME.0000000000000546Sahni S., Lobo-Romero A., Smith T. Contemporary non-hormonal therapies for the management of vasomotor symptoms associated with menopause: A literature review. TouchREV Endocrinol 2021;17(2):133–7. DOI: 10.17925/EE.2021.17.2.133Rios E.R., Venâncio E.T., Rocha N.F. et al. Melatonin: pharmacological aspects and clinical trends. Int J Neurosci 2010;120(9):583–90. DOI: 10.3109/00207454.2010.492921Ezzati M., Velaei K., Kheirjou R. Melatonin and its mechanism of action in the female reproductive system and related malignancies. Mol Cell Biochem 2021;476(8):3177–90. DOI: 10.1007/s11010-021-04151-zDodda B.R., Bondi C.D., Hasan M. et al. Co-administering melatonin with an estradiol-progesterone menopausal hormone therapy represses mammary cancer development in a mouse model of HER2-positive breast cancer. Front Oncol 2019;9:525. DOI: 10.3389/fonc.2019.00525Van Barele M., Heemskerk-Gerritsen B.A.M., Louwers Y.V. et al. Estrogens and progestogens in triple negative breast cancer: Do they harm? Cancers (Basel) 2021;13(11):2506. DOI: 10.3390/cancers13112506